China is striving to become the global leader in biopharmaceuticals, but many of its policy steps are “innovation mercantilist” in nature. This not only is expected to threaten U.S. leadership, but also slow global life sciences innovation, with negative consequences for cures and treatments.
September 18, 2019
Policymakers should recognize that the potential of data-driven drug development is crucial to the well-being of Americans as well as U.S. competitiveness, and develop policies to accelerate this transformation.
September 9, 2019
Academic studies consistently show that a reduction in current drug revenues leads to a fall in future research and the number of new drug discoveries.
August 12, 2019
China is challenging the United States for market share and jobs in one of the highest value-added, most innovation-intensive industries—and the risks extend not just to the U.S. economy, but to global biopharma innovation.
August 6, 2019
As Eline Chivot writes in Health Europa, EU policymakers should call for France and Germany to lift their bans on direct-to-consumer genetic testing and instead harmonize laws to create a single market.
June 20, 2019
ITIF hosted an expert panel discussion on impact drug-price controls have and what effect, if any, mandated drug-price reductions would have on biopharmaceutical innovation and U.S. industry competitiveness.
June 6, 2019
The United States must stand up for innovation in the debate over the U.S.-Mexico-Canada Agreement (USMCA), ITIF's Stephen Ezell, the Macdonald-Laurier Institute's Richard Owens, and Fundacion Idea's Alberto Saracho write in The Hill.
May 20, 2019
Fact of the Week: Chinese Patents Received 90 Percent as Many Citations as Other Countries From 2001 to 2009, but only 32 Percent as Many Foreign Citations
China’s patent output has grown dramatically in recent years, both in terms of the volume of patents submitted for international protection under the Patent Cooperation Treaty (PCT) and in terms of the number of citations those patents receive, a standard measure of a patent’s importance. New research breaking down the sources of those citations raises significant doubts about whether the growth in Chinese patent citations is as meaningful as it appears.
May 16, 2019
Testimony Before the House Oversight Committee on Drug Prices, Intellectual Property, and Biomedical Innovation
In testimony before the House Oversight Committee, Stephen Ezell explained why the United States leads the world in life-sciences innovation; how the public and private sectors contribute; why innovation depends on the ability to generate revenues; the consequences of price controls; and how best to control health-care costs.
April 22, 2019
Debates over drug pricing often consider the impacts on health and innovation, but rarely examine the costs those drugs offset. According to new research examining drug releases for 67 diseases across 15 countries in the three decades from 1982 to 2015, these offsets are dramatic.
April 15, 2019
Seven case studies showcase how IP rights are enabling innovators in Latin America to help solve some of the greatest global health challenges.